Results 61 to 70 of about 5,276 (179)

Targeting EZH2 in Cancer: From Molecular Mechanisms to Clinical Translation

MedComm – Oncology, Volume 5, Issue 2, June 2026.
The abnormal overexpression or gain‐of‐function mutations of EZH2 play a significant role in cancer occurrence and progression, highlighting the importance and potential of EZH2 as a cancer biomarker. Therefore, screening for effective and safe small‐molecule inhibitors, degraders, and natural compounds targeting EZH2 through preclinical cancer models ...
Xi Zhong, Jieni Li, Mingxuan Pan, Xiaoxue Ke, Hongjuan Cui   +4 more
wiley   +1 more source

Neoadjuvant chemotherapy for soft‐tissue sarcoma of the extremities: A post‐hoc Sarculator‐based risk analysis of the EORTC 62961–ESHO 95 randomized trial

Cancer, Volume 132, Issue 9, 1 May 2026.
Abstract Background In the EORTC 62961–ESHO 95 randomized trial (European Organization for Research and Treatment 62961–European Society of Hyperthermia Oncology 95; ClinicalTrials.gov identifier NCT00003052), neoadjuvant chemotherapy (NAC) combined with regional hyperthermia (RHT) improved survival in patients with soft tissue sarcoma (tumor size >5 ...
Markus Albertsmeier, Valeria Milani, Lars H. Lindner, Gabriele Tinè, Sandro Pasquali, Dario Callegaro, Alessandro Gronchi, Hans‐Roland Dürr, Alexander Klein, Dorit Di Gioia, Sultan Abdel‐Rahman, Michael Schmidt, Jens Werner, Michael von Bergwelt‐Baildon, Rosalba Miceli, Rolf Issels   +15 more
wiley   +1 more source

Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma

Journal of Cellular Physiology, Volume 241, Issue 5, May 2026.
ABSTRACT Cancer cells rewire their metabolism to sustain a high proliferation rate. Sensing external cues is essential to match the metabolic fluxes of the cells to the external stimuli. As part of the glucose metabolism, the hexosamine biosynthesis pathway (HBP) is considered a nutrient‐sensing pathway. The HBP produces UDP‐GlcNAc, a key precursor for
Pegah Rahimizadeh, Richard Miallot, Chelsea De Bellis, Philippe Jolivet, Joanna Przybyl   +4 more
wiley   +1 more source

Pathogenic Neurofibromatosis type 1 gene variants in tumors of non‐NF1 patients and role of R1276

FEBS Open Bio, Volume 16, Issue 4, Page 803-813, April 2026.
Somatic variants of the neurofibromatosis type 1 (NF1) gene occur across neoplasms without clinical manifestation of the disease NF1. We identified emerging somatic pathogenic NF1 variants and hotspots, for example, at the arginine finger 1276. Those missense variants provide fundamental information about neurofibromin's role in cancer.
Mareike Selig, Swanhild Lohse, Sara Elahi, Nils Hartmann, Stefanie Deckert, Shutian Si, Alexander Desuki, Anja Harder   +7 more
wiley   +1 more source

Optimizing Systemic Therapy for Advanced Sarcomas: Outcomes With Gemcitabine, Docetaxel, Cisplatin, and Everolimus in a Retrospective Single‐Center Study

Cancer Medicine, Volume 15, Issue 4, April 2026.
Late‐line gemcitabine, docetaxel, cisplatin, and everolimus yield a 45.5% objective response rate and prolonged survival in selected advanced sarcoma subtypes. Prognostic stratification was enhanced by ECOG performance status and lymphocyte‐to‐monocyte ratio, highlighting their potential role in treatment individualization. ABSTRACT Background Advanced
Wen‐Chi Wu, I‐Wei Ho, San‐Chi Chen, Paul Chih‐Hsueh Chen, Po‐Kuei Wu, Chao‐Ming Chen, Hung‐Ta Wu, Chung‐Jung Lin, Ta‐Chung Chao, Chueh‐Chuan Yen   +9 more
wiley   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

A Rare Case of Diffuse Extra‐Cranial Schwannomatosis of the Trunk and Limbs

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT Schwannomas are benign peripheral nerve sheath tumors (PNSTs) arising from myelin sheaths, with schwannomatosis characterized by multiple lesions without neurofibromatosis type 1 (NF1) or type 2 (NF2) stigmata. Malignant transformation is rare but documented.
Bernadette Pedun, Ivaan Pitua, Felix Bongomin, Samuel Bugeza, Alex Bakenga, Valeria Nabbosa   +5 more
wiley   +1 more source

Profiling the cancer-prone microenvironment in a zebrafish model for MPNST

Oncogene
Abstract Microenvironmental contributions to soft tissue sarcoma progression are relatively undefined, particularly during sarcoma onset. Use of animal models to reveal these contributions is impeded by difficulties in discriminating between microenvironmental, precancerous, and cancer cells, and challenges in defining a precancerous ...
Cheryl Cero, John S. House, Vincenzo Verdi, Jordan L. Ferguson, Dereje D. Jima, Aubrie A. Selmek, Olivia M. Patania, Jennifer E. Dwyer, Bih-Rong Wei, Dillon T. Lloyd, Heather R. Shive   +10 more
openaire   +2 more sources

Malignant Peripheral Nerve Sheath Tumors: Differentiation Patterns and Immunohistochemical Features - A Mini-Review and Our New Findings

Journal of Cancer, 2012
Malignant peripheral nerve sheath tumors (MPNST) represent a group of highly heterogeneous human malignancies often with multiple histological origins, divergent differentiation patterns, and diverse immunohistochemical presentations.
Aitao Guo, Aijun Liu, Lixin Wei, Xin Song
doaj  

The CoREST complex is a therapeutic vulnerability in malignant peripheral nerve sheath tumors

Scientific Reports
Malignant peripheral nerve sheath tumor (MPNST) is a highly aggressive sarcoma that may be seen in patients with neurofibromatosis type 1 (NF1) or occur sporadically.
Imad Soukar, Robert J. Fisher, Sanjana Bhagavatula, Marianne Collard, Philip A. Cole, Rhoda M. Alani   +5 more
doaj   +1 more source